Allergy Therapeutics PLC (GB:AGY)
LSE:AGY
Want to see GB:AGY full AI Analyst Report?
AGY Stock Chart & Stats
11.80 p
-0.04 p(-0.55%)
At close: 4:00 PM EST
11.80 p
-0.04 p(-0.55%)
Day’s Range― - ―
52-Week Range6.50 p - 12.10 p
Previous CloseN/A
Volume22.64K
Average Volume (3M)460.33K
Market Cap
£550.93M
Enterprise Value470.45M
Total Cash (Recent Filing)£10.08M
Total Debt (Recent Filing)£26.75M
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Sep 24, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding6,332,530,000
10 Day Avg. Volume433,490
30 Day Avg. Volume460,334
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)-13.44
Price to Sales (P/S)6.88
P/FCF Ratio-11.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£68.00M
Bulls Say, Bears Say
Bulls Say
Disease-modifying ModelThe company’s core model targets disease modification via allergen-specific immunotherapy rather than symptomatic relief. That structural focus supports durable demand, higher clinical barriers to entry, and potential for longer treatment lifecycles and stickier customer relationships versus one-off symptomatic therapies.
Specialty Pharma/biologics PositioningPositioning in specialty pharma and biologics aligns with industry trends toward targeted biologic therapies and higher-margin specialty products. This structural market shift can favor companies with R&D and manufacturing capabilities, enabling sustainable revenue upside if clinical and regulatory progress continues.
Operational Scale For R&D & CommercializationA workforce of ~612 indicates operational capacity to run R&D programs and commercial activities concurrently. Sustained headcount and organizational capability increase the likelihood of advancing pipeline assets and supporting existing product rollouts, a durable asset for specialty pharma execution.
Bears Say
Revenue Decline & Heavy LossesMaterial revenue decline and steep net losses signal weakening commercial traction and persistent unprofitability. Over months this erodes internal funding for R&D and commercialization, raises pressure on margins, and increases reliance on external capital, impairing sustainable growth prospects.
Negative Operating / Free Cash FlowConsistently negative operating and free cash flows indicate the business is not generating internal cash to fund operations or development. This structural cash shortfall necessitates ongoing financing, increasing dilution or leverage risk and constraining strategic investments over the medium term.
Stressed Balance Sheet / Negative EquityNegative equity and an inverted debt-to-equity metric reflect a stressed capital structure and limited financial flexibility. This raises refinancing and covenant risk, reduces ability to withstand setbacks, and can elevate funding costs or force asset sales, harming long-term execution capacity.
Allergy Therapeutics News
AGY FAQ
What was Allergy Therapeutics PLC’s price range in the past 12 months?
Allergy Therapeutics PLC lowest share price was 6.50 p and its highest was 12.10 p in the past 12 months.
What is Allergy Therapeutics PLC’s market cap?
Allergy Therapeutics PLC’s market cap is £550.93M.
When is Allergy Therapeutics PLC’s upcoming earnings report date?
Allergy Therapeutics PLC’s upcoming earnings report date is Sep 24, 2026 which is in 111 days.
How were Allergy Therapeutics PLC’s earnings last quarter?
Allergy Therapeutics PLC released its earnings results on Mar 31, 2026. The company reported -0.004 p earnings per share for the quarter, the consensus estimate of -0.004 p by 0 p.
Is Allergy Therapeutics PLC overvalued?
According to Wall Street analysts Allergy Therapeutics PLC’s price is currently Overvalued.
Does Allergy Therapeutics PLC pay dividends?
Allergy Therapeutics PLC does not currently pay dividends.
What is Allergy Therapeutics PLC’s EPS estimate?
Allergy Therapeutics PLC’s EPS estimate is >-0.01.
How many shares outstanding does Allergy Therapeutics PLC have?
Allergy Therapeutics PLC has 6,332,530,000 shares outstanding.
What happened to Allergy Therapeutics PLC’s price movement after its last earnings report?
Allergy Therapeutics PLC reported an EPS of -0.004 p in its last earnings report, expectations of -0.004 p. Following the earnings report the stock price went down -1.905%.
Which hedge fund is a major shareholder of Allergy Therapeutics PLC?
Currently, no hedge funds are holding shares in GB:AGY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Allergy Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
82.35%
12-Months-Change
Fundamentals
Return on Equity
409.00%
Trailing 12-Months
Asset Growth
-2.69%
Trailing 12-Months
Company Description
Allergy Therapeutics PLC
Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. The company also develops allergy vaccines for trees, grass, house dust mite, and pets with fur/hair, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.
Technical Analysis
Animalcare
―
Hikma Pharmaceuticals
―
Shield Therapeutics
―
Venture Life
―
Beximco Pharmaceuticals Limited Sponsored GDR RegS
―
Options Prices
Currently, No data available
---